Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update.

Autor: Elangbam CS; Department of Pathology and GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709, USA. cse63957@GlaxoWellcome.com, Tyler RD, Lightfoot RM
Jazyk: angličtina
Zdroj: Toxicologic pathology [Toxicol Pathol] 2001 Mar-Apr; Vol. 29 (2), pp. 224-31.
DOI: 10.1080/019262301317052495
Abstrakt: Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely alpha, delta, and gamma have been identified with distinct tissue distribution patterns and metabolic functions. PPAR-alpha is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-gamma is highly expressed in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-delta shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-alpha and PPAR-gamma) have beneficial effects in inflammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fibrinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.
Databáze: MEDLINE